Bausch + Lomb/$BLCO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bausch + Lomb
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Ticker
$BLCO
Sector
Primary listing
NYSE
Industry
Health Care Equipment and Supplies
Headquarters
Vaughan, Canada
Employees
13,500
Website
Bausch + Lomb Metrics
BasicAdvanced
$5.1B
-
-$1.03
0.58
-
Price and volume
Market cap
$5.1B
Beta
0.58
52-week high
$21.69
52-week low
$10.45
Average daily volume
774K
Financial strength
Current ratio
1.561
Quick ratio
0.71
Long term debt to equity
74.444
Total debt to equity
75.066
Interest coverage (TTM)
0.29%
Profitability
EBITDA (TTM)
545
Gross margin (TTM)
60.03%
Net profit margin (TTM)
-7.50%
Operating margin (TTM)
2.69%
Effective tax rate (TTM)
-8.95%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
0.61%
Return on equity (TTM)
-5.36%
Valuation
Price to revenue (TTM)
1.044
Price to book
0.8
Price to tangible book (TTM)
-3.1
Price to free cash flow (TTM)
-30.023
Free cash flow yield (TTM)
-3.33%
Free cash flow per share (TTM)
-47.70%
Growth
Revenue change (TTM)
11.94%
Earnings per share change (TTM)
6.69%
3-year revenue growth (CAGR)
8.57%
3-year earnings per share growth (CAGR)
27.15%
Bulls say / Bears say
Bausch + Lomb's acquisition of Novartis's dry-eye drug Xiidra for $1.75 billion, along with additional pipeline assets, is expected to strengthen its pharmaceutical portfolio and drive future revenue growth. (bloomberg.com)
The company's revenue for the fourth quarter of 2023 increased by 18% year-over-year, indicating strong operational performance and market demand. (marketinference.com)
Analysts project Bausch + Lomb's earnings to grow by 29.73% in the coming year, suggesting positive investor sentiment and potential stock appreciation. (marketbeat.com)
In Q1 2025, Bausch + Lomb reported a loss of $0.07 per share, missing the Zacks Consensus Estimate of $0.03, which may raise concerns about profitability. (nasdaq.com)
The company's stock price has declined approximately 24% since the beginning of 2025, underperforming the S&P 500's decline of 5.5%, indicating potential investor apprehension. (nasdaq.com)
Bausch + Lomb's parent company, Bausch Health, faces a substantial debt burden of $21 billion, which could impact the subsidiary's financial stability and strategic flexibility. (ft.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
Bausch + Lomb News
AllArticlesVideos
Bausch + Lomb Combines Patient Voices and New Survey Insights to Combat Persistent Misconceptions about Dry Eye
Business Wire·4 weeks ago
Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13
Business Wire·4 weeks ago
Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Continues – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bausch + Lomb stock?
Bausch + Lomb (BLCO) has a market cap of $5.1B as of July 28, 2025.
What is the P/E ratio for Bausch + Lomb stock?
The price to earnings (P/E) ratio for Bausch + Lomb (BLCO) stock is 0 as of July 28, 2025.
Does Bausch + Lomb stock pay dividends?
No, Bausch + Lomb (BLCO) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next Bausch + Lomb dividend payment date?
Bausch + Lomb (BLCO) stock does not pay dividends to its shareholders.
What is the beta indicator for Bausch + Lomb?
Bausch + Lomb (BLCO) has a beta rating of 0.58. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.